Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akito Hata

Showing results (91-100 of 146) with videos related to

Pageof 15
Sort By:
Anticancer Research|January 10, 2014
Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancerAkito Hata, Nobuyuki Katakami, Kosuke Tanaka, et al.
Bioorganic & Medicinal Chemistry|June 24, 2017
Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitusHideki Hirose, Takeshi Yamasaki, Masaki Ogino, et al.
Cancer|September 8, 2018
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Journal of Medicinal Chemistry|July 13, 2017
Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart FailureTomohiro Okawa, Yoshio Aramaki, Mitsuo Yamamoto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 9, 2016
EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III AdenocarcinomaKosuke Tanaka, Toyoaki Hida, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)|July 21, 2022
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitisTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Lung Cancer (Amsterdam, Netherlands)|July 5, 2015
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancerAkihiro Nishiyama, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2018
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid responseAkito Nakamura, Tadahiro Nambu, Shunsuke Ebara, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2015
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)Kazumi Nishino, Fumio Imamura, Toru Kumagai, et al.
Investigational New Drugs|January 6, 2021
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort studyTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Pageof 15

Showing results (91-100 of 146) with videos related to

Sort By:
Pageof 15
Anticancer Research|January 10, 2014
Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancerAkito Hata, Nobuyuki Katakami, Kosuke Tanaka, et al.
Bioorganic & Medicinal Chemistry|June 24, 2017
Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitusHideki Hirose, Takeshi Yamasaki, Masaki Ogino, et al.
Cancer|September 8, 2018
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)Akito Hata, Nobuyuki Katakami, Reiko Kaji, et al.
Journal of Medicinal Chemistry|July 13, 2017
Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart FailureTomohiro Okawa, Yoshio Aramaki, Mitsuo Yamamoto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 9, 2016
EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III AdenocarcinomaKosuke Tanaka, Toyoaki Hida, Yuko Oya, et al.
Lung Cancer (Amsterdam, Netherlands)|July 21, 2022
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitisTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Lung Cancer (Amsterdam, Netherlands)|July 5, 2015
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancerAkihiro Nishiyama, Nobuyuki Katakami, Hiroshige Yoshioka, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2018
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid responseAkito Nakamura, Tadahiro Nambu, Shunsuke Ebara, et al.
Lung Cancer (Amsterdam, Netherlands)|June 22, 2015
A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110)Kazumi Nishino, Fumio Imamura, Toru Kumagai, et al.
Investigational New Drugs|January 6, 2021
Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort studyTakeya Sugimoto, Daichi Fujimoto, Yuki Sato, et al.
Pageof 15